ATM kinase

By Targets:	ATM/ATR (16) Apoptosis (1) Checkpoint Kinase (Chk) (1) mTOR (3) PDGFR (1) PI3K (2) PROTACs (1) VEGFR (1)
By Research Areas:	Cancer (18)

Targets Recommended: ATM/ATR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150617

Lartesertib

M4076; ATM Inhibitor-5
ATM/ATR Cancer

Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1) .
HY-153787

ATM Inhibitor-6

ATM/ATR Cancer

ATM inhibitor-6 (A-193) is a selective ATM kinase inhibitor. ATM inhibitor-6 can be used in cancer research .

Lartesertib M4076; ATM Inhibitor-5	ATM/ATR	Cancer
Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase *ATM* (extracted from patent WO2022058351A1) .

ATM Inhibitor-6	ATM/ATR	Cancer
ATM inhibitor-6 (A-193) is a selective *ATM* kinase inhibitor. ATM inhibitor-6 can be used in cancer research .

HY-150617A

(Rac)-Lartesertib (Rac)-M4076; (Rac)-ATM Inhibitor-5	ATM/ATR	Cancer
(Rac)-Lartesertib ((Rac)-M4076; (Rac)-ATM Inhibitor-5) is an isoform of Lartesertib (HY-150617), which is a potent inhibitor of serine/threonine protein kinase *ATM* (extracted from patent WO2022058351A1) .

HY-155091

ATM Inhibitor-9

ATM/ATR Cancer

ATM Inhibitor-9 (Compd 7a) is a potent ATM inhibitor with IC₅₀5 nM for ATM kinase, useful in cancer research .

ATM Inhibitor-9	ATM/ATR	Cancer
ATM Inhibitor-9 (Compd 7a) is a potent *ATM* inhibitor with IC₅₀5 nM for ATM kinase, useful in cancer research .

HY-144686

ATM Inhibitor-3	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-3 (compound 34) is a potent and selective *ATM* inhibitor, with an IC₅₀ of 0.71 nM. ATM Inhibitor-3 shows inhibition of PI3K kinases family. ATM Inhibitor-3 exhibits favorable metabolic stability .

HY-144687

ATM Inhibitor-4	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-4 (compound 39) is a potent and selective *ATM* inhibitor, with an IC₅₀ of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability .

HY-12061

KU-60019

Maximum Cited Publications

15 Publications Verification

ATM/ATR Cancer

KU-60019 is an improved ATM kinase-specific inhibitor with IC₅₀ of 6.3 nM.

KU-60019 Maximum Cited Publications 15 Publications Verification	ATM/ATR	Cancer
KU-60019 is an improved *ATM* kinase-specific inhibitor with IC₅₀ of 6.3 nM.

HY-141478

Antitumor agent-28	ATM/ATR	Cancer
Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity .

HY-112198

AZ31	ATM/ATR	Cancer
AZ31 is a a potent, highly selective, and orally active *ATM* inhibitor with an IC₅₀ of <1.2 nM for ATM enzyme, and an IC₅₀ of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .

HY-157767

Abd110	PROTACs ATM/ATR	Cancer
Abd110 (compound 42i) is a Lenalidomide-based PROTAC ATR kinase degrader. Abd110 selectively decreases ATR and phospho-ATR without affecting related kinases ATM and DNA-PKcs .

HY-157941

ART0380	ATM/ATR	Cancer
ART0380 is a potent and selective ATR kinase inhibitor. ART0380 has selective antitumor activity that can be used for the research of Ataxia-Telangiectasia Mutated (ATM) aberrant cancers .

HY-117693

Mirin 1 Publications Verification	ATM/ATR	Cancer
Mirin is a potent Mre11-Rad50-Nbs1 (MRN) complex inhibitor. Mirin prevents MRN-dependent activation of ATM (IC₅₀=12 μM) without affecting ATM protein kinase activity, and it inhibits Mre11-associated exonuclease activity. Mirin abolishes the G2/M checkpoint and homology-dependent repair in mammalian cells. Mirin prevents ATM activation in response to DNA double-strand breaks (DSBs) and blocks homology-directed repair (HDR) in mammalian cells .

HY-144217

SKLB-197	ATM/ATR	Cancer
SKLB-197 showed an IC₅₀ value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.

HY-19959

(Z)-Mirin 5 Publications Verification	ATM/ATR Apoptosis	Cancer
(Z)-Mirin is an MRN (Mre11-Rad50-Nbs1) inhibitor. (Z)-Mirin prevents MRN-dependent activation of ATM without affecting ATM protein kinase activity. (Z)-Mirin inhibits Mre11-associated exonuclease activity. (Z)-Mirin increases apoptosis, triggers a G2/M checkpoint and strongly inhibits homology-directed repair (HDR) .

HY-11002

CP-466722 4 Publications Verification	ATM/ATR	Cancer
CP-466722 is a rapidly reversible inhibitor of *ATM, with an IC₅₀* of 0.41 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members.

HY-139609

Camonsertib RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-119757

Tyrphostin AG1433 SU1433; AG1433	PDGFR VEGFR	Cancer
Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC₅₀s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation .

HY-112477

Chk2-IN-1	Checkpoint Kinase (Chk)	Cancer
Chk2-IN-1 (compound 1) is a potent and selective inhibitor of *checkpoint kinase* 2 (Chk2), with IC₅₀s of 13.5 nM and 220.4 nM for Chk2 and Chk1*, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM*)-dependent Chk2-mediated radioprotection effect .

Cat. No.	Product Name

HY-L004

Cell Cycle/DNA Damage Compound Library	2037 compounds
DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair. MCE owns a unique collection of 2037 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Cell Cycle/DNA Damage Compound Library

2037 compounds

DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.

MCE owns a unique collection of 2037 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Cat. No.	Product Name	Application	Reactivity

HY-P83436

Phospho-ATM (Ser1981) Antibody (YA3181)

ATM; Serine-protein kinase ATM; Ataxia telangiectasia mutated; A-T mutated
WB, IHC-P, ICC/IF, IP Human

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.